GRFS – Grifols, S.A.
Grifols, S.A.GRFS
$7.45Name : Grifols, S.A.
Sector : Healthcare
Industry: Drug Manufacturers - General
Mark. Cap: $6,044,423,168.00
EPSttm : 0.25
Grifols, S.A.
$7.45
1.06%$0.08Float Short %
1.22
Margin Of Safety %
30
Put/Call OI Ratio
0.71
EPS Next Q Diff
EPS Last/This Y
EPS This/Next Y
0.21
Price
7.44
Target Price
11.37
Analyst Recom
2.75
Performance Q
-19.2
Relative Volume
0.6
Beta
0.4
Ticker: GRFS
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-01-23 | GRFS | 7.48 | 0.61 | 1.98 | 6234 |
| 2025-01-24 | GRFS | 7.35 | 0.69 | 999.99 | 6944 |
| 2025-01-27 | GRFS | 7.24 | 0.69 | 4.25 | 6955 |
| 2025-01-28 | GRFS | 7.18 | 0.70 | 2.38 | 6986 |
| 2025-01-29 | GRFS | 7.01 | 0.70 | 0.63 | 7010 |
| 2025-01-30 | GRFS | 6.91 | 0.69 | 1.29 | 7042 |
| 2025-01-31 | GRFS | 6.91 | 0.69 | 0.08 | 7057 |
| 2025-02-03 | GRFS | 6.61 | 0.69 | 0.19 | 7080 |
| 2025-02-04 | GRFS | 6.82 | 0.68 | 999.99 | 7135 |
| 2025-02-05 | GRFS | 7.07 | 0.68 | 30.00 | 7155 |
| 2025-02-06 | GRFS | 7 | 0.69 | 6.45 | 7202 |
| 2025-02-07 | GRFS | 7.11 | 0.71 | 999.99 | 7271 |
| 2025-02-10 | GRFS | 6.99 | 0.71 | 0.19 | 7271 |
| 2025-02-11 | GRFS | 7.16 | 0.70 | 4.62 | 7309 |
| 2025-02-12 | GRFS | 7.01 | 0.71 | 0.48 | 7352 |
| 2025-02-13 | GRFS | 7.46 | 0.70 | 0.47 | 7381 |
| 2025-02-14 | GRFS | 7.33 | 0.69 | 2.81 | 7405 |
| 2025-02-18 | GRFS | 7.4 | 0.69 | 1.96 | 7450 |
| 2025-02-19 | GRFS | 7.37 | 0.71 | 0.06 | 7471 |
| 2025-02-20 | GRFS | 7.53 | 0.71 | 1.92 | 7464 |
| 2025-02-21 | GRFS | 7.45 | 0.71 | 1.12 | 7492 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-01-23 | GRFS | 7.47 | - | - | 0.83 |
| 2025-01-24 | GRFS | 7.35 | - | - | 0.83 |
| 2025-01-27 | GRFS | 7.24 | - | - | 0.83 |
| 2025-01-28 | GRFS | 7.18 | - | - | 0.83 |
| 2025-01-29 | GRFS | 7.01 | - | - | 0.83 |
| 2025-01-30 | GRFS | 6.91 | - | - | 0.83 |
| 2025-01-31 | GRFS | 6.91 | - | - | 0.83 |
| 2025-02-03 | GRFS | 6.62 | - | - | 0.83 |
| 2025-02-04 | GRFS | 6.82 | - | - | 0.83 |
| 2025-02-05 | GRFS | 7.03 | - | - | 0.83 |
| 2025-02-06 | GRFS | 7.00 | - | - | 0.83 |
| 2025-02-07 | GRFS | 7.11 | - | - | 0.83 |
| 2025-02-10 | GRFS | 6.98 | - | - | 0.83 |
| 2025-02-11 | GRFS | 7.16 | - | - | 0.83 |
| 2025-02-12 | GRFS | 7.01 | - | - | 0.83 |
| 2025-02-13 | GRFS | 7.47 | - | - | 0.83 |
| 2025-02-14 | GRFS | 7.32 | - | - | 0.83 |
| 2025-02-18 | GRFS | 7.40 | - | - | 0.83 |
| 2025-02-19 | GRFS | 7.38 | - | - | 0.83 |
| 2025-02-20 | GRFS | 7.54 | - | - | 0.83 |
| 2025-02-21 | GRFS | 7.44 | - | - | 0.83 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-01-23 | GRFS | 0.00 | 4.75 | 1.44 |
| 2025-01-24 | GRFS | 0.00 | 4.75 | 1.44 |
| 2025-01-27 | GRFS | 0.00 | 3.91 | 1.44 |
| 2025-01-28 | GRFS | 0.00 | 3.91 | 1.37 |
| 2025-01-29 | GRFS | 0.00 | 3.91 | 1.37 |
| 2025-01-30 | GRFS | 0.00 | 3.91 | 1.37 |
| 2025-01-31 | GRFS | 0.00 | 3.91 | 1.36 |
| 2025-02-03 | GRFS | 0 | 4.86 | 1.37 |
| 2025-02-04 | GRFS | 0.00 | 4.86 | 1.37 |
| 2025-02-05 | GRFS | 0.00 | 4.86 | 1.37 |
| 2025-02-06 | GRFS | 0.00 | 4.86 | 1.37 |
| 2025-02-07 | GRFS | 0.00 | 4.86 | 1.37 |
| 2025-02-10 | GRFS | 0.00 | 4.43 | 1.36 |
| 2025-02-11 | GRFS | 0 | 4.43 | 1.36 |
| 2025-02-12 | GRFS | 0 | 4.43 | 1.22 |
| 2025-02-13 | GRFS | 0 | 4.43 | 1.22 |
| 2025-02-14 | GRFS | 0.00 | 4.43 | 1.22 |
| 2025-02-18 | GRFS | 0.00 | 3.89 | 1.22 |
| 2025-02-19 | GRFS | 0.00 | 3.89 | 1.22 |
| 2025-02-20 | GRFS | 0.00 | 3.89 | 1.22 |
| 2025-02-21 | GRFS | 0.00 | 3.89 | 1.22 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
Avg. EPS Est. Current Quarter
0.23
Avg. EPS Est. Next Quarter
Insider Transactions
Institutional Transactions
3.89
Beta
0.4
Average Sales Estimate Current Quarter
1863
Average Sales Estimate Next Quarter
Fair Value
9.7
Quality Score
90
Growth Score
93
Sentiment Score
78
Actual DrawDown %
71.1
Max Drawdown 5-Year %
-77.8
Target Price
11.37
P/E
29.7
Forward P/E
8.04
PEG
0.61
P/S
0.27
P/B
0.84
P/Free Cash Flow
EPS
0.25
Average EPS Est. Cur. Y
0.83
EPS Next Y. (Est.)
1.05
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
2.4
Relative Volume
0.6
Return on Equity vs Sector %
-16.2
Return on Equity vs Industry %
-23.9
EPS 1 7Days Diff
0.2
EPS 1 30Days Diff
0.22
EBIT Estimation
Grifols, S.A.Sector: Healthcare
Industry: Drug Manufacturers - General
Employees: 23000
Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.
stock quote shares GRFS – Grifols, S.A. Stock Price stock today
news today GRFS – Grifols, S.A. stock forecast ,stock prediction 2023 2024 2025
marketwatch GRFS – Grifols, S.A. yahoo finance google finance
stock history GRFS – Grifols, S.A. invest stock market
stock prices GRFS premarket after hours
ticker GRFS fair value insiders trading